Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome

Oncology Letters

Volumn 8, Issue 4, 2014, Pages 1523-1527

  Takai, Mihoko ^a   Yamauchi, Takahiro ^a   Fujita, Kei ^a   Lee, Shin ^a   Ookura, Miyuki ^a   Kishi, Shinji ^a   Urasaki, Yoshimasa ^a   Yoshida, Akira ^a   Iwasaki, Hiromichi ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Febuxostat; Hematological malignancy; Hyperuricemia; Tumor lysis syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; CYCLOSPORIN; FEBUXOSTAT; FENOFIBRATE; LOSARTAN; PYRAZINAMIDE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERURICEMIA; HYPONATREMIA; LARGE CELL LYMPHOMA; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PLASMA CLEARANCE; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; VOMITING;

EID: 84922433371     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2394     Document Type: Article

References (30)

1. Cohen LF, Balow JE, Magrath IT, Poplack DG and Ziegler JL: Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 68:486-491, 1980.
2. Coiffier B, Altman A, Pui CH, Younes A and Cairo MS: Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26: 2767-2778, 2008.
3. Cairo MS, Coiffier B, Reiter A and Younes A; TLS Expert Panel: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149: 578-586, 2010.
4. Howard SC, Jones DP and Pui CH: The tumor lysis syndrome. N Engl J Med 364: 1844-1854, 2011.
5. Firwana BM, Hasan R, Hasan N, Alahdab F, Alnahhas I, Hasan S and Varon J: Tumor lysis syndrome: a systematic review of case series and case reports. Postgrad Med 124: 92-101, 2012.
6. Cairo MS and Bishop M: Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3-11, 2004.
7. Hande KR and Garrow GC: Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 94: 133-139, 1993.
8. Will A and Tholouli E: The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol 154: 3-13, 2011.
9. Massey V, Komai H, Palmer G and Elion GB: On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem 245: 2837-2844, 1970.
10. Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J and Tonelli M: A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 43: 367-375, 2013.
11. Bruce SP: Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 40: 2187-2194, 2006.
12. Schumacher HR Jr, Becker MA, Wortmann RL, et al: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59: 1540-1548, 2008.
13. Edwards NL: Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford) 48: ii15-ii19, 2009.
14. Burns CM and Wortmann RL: Gout therapeutics: new drugs for an old disease. Lancet 377: 165-177, 2011.
15. Garcia-Valladares I, Khan T and Espinoza LR: Efficacy and safety of febuxostat in patients with hyperuricemia and gout. Ther Adv Musculoskelet Dis 3: 245-253, 2011.
16. The guideline revising committee of Japanese Society of Gout and Nucleic Acid Metabolism. Digest of Guideline for the management of hyperuricemia and gout, 2nd edition. Gout Nucleic Acid Metabol 34: 107-143, 2010 (In Japanese).
17. Cortes J, Moore JO, Maziarz RT, et al: Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. J Clin Oncol 28: 4207-4213, 2010.
18. Kikuchi A, Kigasawa H, Tsurusawa M, et al: A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int J Hematol 90: 492-500, 2009.
19. Yamauchi T, Negoro E, Lee S, et al: A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res 33: 3947-3951, 2013.
20. Inai K, Tsutani H and Ueda T: Hyperuricemia associated with hematological malignancies. Gout and Nucleic Acid Metabolism 23: 181-186, 1999 (In Japanese).
21. de Bont JM and Pieters R: Management of hyperuricemia with rasburicase review. Nucleosides Nucleotides Nucleic Acids 23: 1431-1440, 2004.
22. Rampello E, Fricia T and Malaguarnera M: The management of tumor lysis syndrome. Nat Clin Pract Oncol 3: 438-447, 2006.
23. Andreoli SP, Clark JH, McGuire WA and Bergstein JM: Purine excretion during tumor lysis in children with acute lymphocytic leukaemia receiving allopurinol: relationship to acute renal failure. J Pediatr 109: 292-298, 1986.
24. Navolanic PM, Pui CH, Larson RA, et al: Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January, 2002. Leukaemia 17: 499-514, 2003.
25. Cheson BD and Dutcher BS: Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol 3:117-124, 2005.
26. Arellano F and Sacristan JA: Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 27: 337-343, 1993.
27. Hande KR, Noone RM and Stone WJ: Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76: 47-56, 1984.
28. Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N and Vernillet L: The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics and safety of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase. J Clin Pharmacol 46: 88-102, 2006.
29. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E and Lademacher C: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12: R63, 2010.
30. Vadhan-Raj S, Fayad LE, Fanale MA, et al: A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23: 1640-1645, 2012.